Enwei Pharmaceutical Co., Ltd. (SHE:301331)

Enwei Pharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Cash & Equivalents	338.15	362.31	370.27	236.12	341.58	64.25
Trading Asset Securities	142.94	171.28	144.72	157.16	236.56	14.4
Cash & Short-Term Investments	481.09	533.58	515	393.28	578.14	78.65
Cash Growth	-8.35%	3.61%	30.95%	-31.97%	635.07%	1.59%
Accounts Receivable	216.36	309.72	296.53	265	245.28	192.91
Other Receivables	4.12	3.06	3.69	3.99	4.17	3.98
Receivables	220.48	312.78	300.22	268.98	249.45	196.89
Inventory	125.79	101.1	115.55	107.37	104.65	110.01
Other Current Assets	30.23	28	21.27	17.23	25.06	28.21
Total Current Assets	857.59	975.46	952.04	786.86	957.29	413.77
Property, Plant & Equipment	269.35	264.9	246.55	231.12	240	241.77
Long-Term Investments	28	20	0.37	0.37	0.35	0.42
Goodwill	100.55	100.55	100.55	100.55	100.55	100.55
Other Intangible Assets	105.39	117.28	133.37	148.04	42.08	47.45
Long-Term Deferred Tax Assets	4.06	3.89	4.64	3.05	1.8	1.74
Long-Term Deferred Charges	10.89	13.45	8.7	10.68	16.83	18.28
Other Long-Term Assets	61.77	55.13	58.3	56.81	47.18	45.11
Total Assets	1,438	1,551	1,505	1,337	1,406	869.09

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Accounts Payable	28.86	56.48	49.49	30.94	36.88	33.64
Accrued Expenses	26.4	136.32	132.83	141.69	141.02	128.52
Current Portion of Long-Term Debt	11.96	185.07	10.09	-	-	-
Current Portion of Leases	-	1.53	1.27	0.88	-	-
Current Income Taxes Payable	9.71	5.19	6.52	10.21	11.23	8.19
Current Unearned Revenue	27.44	19.73	24.61	14.01	28.15	16.15
Other Current Liabilities	92.64	50.68	13.6	12.04	10.31	12.73
Total Current Liabilities	197	454.99	238.42	209.77	227.58	199.22
Long-Term Debt	190	-	185	-	-	-
Long-Term Leases	0.76	1.44	1.52	0.46	-	-
Long-Term Unearned Revenue	6.91	8.79	9.96	11.92	14.05	15.88
Long-Term Deferred Tax Liabilities	13.75	12.64	11.96	12.17	11.45	11.74
Total Liabilities	408.42	477.86	446.86	234.31	253.08	226.84

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Common Stock	102.89	102.89	102.89	70.14	70.14	52.6
Additional Paid-In Capital	632.9	630.96	638.71	671.51	664.63	239.22
Retained Earnings	326.5	373.35	375.25	392.32	418.23	350.43
Treasury Stock	-33.12	-34.4	-59.18	-30.78	-	-
Total Common Equity	1,029	1,073	1,058	1,103	1,153	642.25
Shareholders' Equity	1,029	1,073	1,058	1,103	1,153	642.25
Total Liabilities & Equity	1,438	1,551	1,505	1,337	1,406	869.09

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Total Debt	202.72	188.04	197.88	1.34	-	-
Net Cash (Debt)	278.37	345.54	317.12	391.94	578.14	78.65
Net Cash Growth	-16.37%	8.96%	-19.09%	-32.21%	635.07%	1.59%
Net Cash Per Share	2.64	3.35	3.14	3.81	6.85	1.01
Filing Date Shares Outstanding	102.91	101.88	101.08	100.99	103.8	77.85
Total Common Shares Outstanding	102.91	101.84	101.08	102.76	103.8	77.85
Working Capital	660.59	520.47	713.62	577.09	729.7	214.55
Book Value Per Share	10.00	10.53	10.46	10.74	11.11	8.25
Tangible Book Value	823.23	854.97	823.74	854.59	1,010	494.25
Tangible Book Value Per Share	8.00	8.40	8.15	8.32	9.73	6.35
Buildings	-	289.03	289.03	287.63	275.1	274.06
Machinery	-	315.25	301.77	302.77	271.99	263.51
Construction In Progress	-	64.46	40.37	8.82	35.68	23.84

Data Source: S&P Global Market Intelligence Last updated: Oct 25, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 12, 2026

Data Sources Report a data error